Open AccessPreoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Author(s) -
Guido Scoccianti,
Francesca Totti,
Maurizio Scorianz,
Giacomo Giulio Baldi,
Giuliana Roselli,
Giovanni Beltrami,
Alessandro Franchi,
Rodolfo Capanna,
Domenico Andrea Campanacci
Publication year - 2018
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.178
H-Index - 204
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1007/s11999.0000000000000104
Subject(s) - denosumab , medicine , curettage , surgery , cryotherapy , giant cell tumor of bone , teriparatide , zoledronic acid , osteoporosis , giant cell , bone mineral , pathology
Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used for treatment of giant cell tumor of bone (GCTB). In GCTB, denosumab has been used as a single agent in patients with inoperable tumors; it also has been used before surgery in some patients with the aim to downstage the tumor to facilitate a joint-preserving procedure (curettage) rather than a resection. However, few studies are available evaluating the benefits and risks of denosumab for the latter indication.